Treatment strategies have not been well established for thrombotic microangiopathy associated with malignant hypertension.

Two posters highlighted the effects of sacubitril/valsartan (Entresto; Novartis) on key biomarkers and cardiac function in ...

Sacubitril/valsartan may be a better treatment option compared with ACEi/ARBs for patients with malignant hypertension-associated thrombotic microangiopathy. Kidney recovery is better when ...

Researchers have established that sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is not superior to enalapril in the treatment of heart failure (HF) in children who have ...

Medically reviewed by Richard N. Fogoros, MDMedically reviewed by Richard N. Fogoros, MD Guideline-directed medical therapy (GDMT) for heart failure describes evidence-based therapies that ...

Both sacubitril/valsartan (Entresto) and enalapril (Vasotec) were associated with improvement in clinical measures among children aged 1 month to younger than 18 years who had heart failure ...

Read also: Biocon arm gets USFDA nod for chronic heart failure drug Sacubitril/Valsartan Medical Dialogues team had earlier reported that the USFDA had concluded a combined cGMP inspection and ...

Both presence and extent of LGE were associated with all-cause mortality, CV mortality, arrhythmia, HF events, and MACE in patients with nonischemic dilated cardiomyopathy (NIDCM). Of note, higher ...

It is imperative that clinicians understand the differences in each patient and how effective therapies must be individualized and often combined to treat patients with varying profiles. Efforts to ...